Piper Sandler initiates 10X Genomics stock coverage with Neutral rating

Piper Sandler initiated coverage on 10X Genomics (TXG) with a Neutral rating and a $15.00 price target, acknowledging the company's leading position in the single-cell market, strong financial health, and potential in spatial technologies. Despite these strengths and a significant Q2 2025 earnings beat (EPS of $0.28 vs. -$0.37 forecast, revenue exceeding expectations by 24%), the firm cited ongoing price compression in the single-cell market and the multi-year development timeline for spatial technologies as reasons for caution, leading to an after-hours stock decline post-earnings.

Analysis

Piper Sandler has initiated coverage on 10X Genomics (TXG) with a Neutral rating and a $15.00 price target, framing the company as a leader with a complex near-term outlook. The analysis recognizes TXG's dominant position in the single-cell market, supported by the largest install base and key technological advantages. Furthermore, the company's financial health is robust, as evidenced by a current ratio of 5.84 and a balance sheet holding more cash than debt. Despite these strengths and a significant Q2 2025 performance—where revenue reached $173 million (a 24.03% beat) and EPS was $0.28 against a forecasted loss of -$0.37—the market reaction was negative, with the stock declining in after-hours trading. This disconnect is attributed to the primary concerns cited by Piper Sandler: persistent price compression in the core single-cell market and the multi-year development timeline required for the high-potential spatial technology market to mature. The firm's cautious stance suggests that while TXG has a promising long-term growth trajectory comparable to the Next Generation Sequencing (NGS) market, current macroeconomic and industry-specific headwinds justify a wait-and-see approach.

Key Decisions for Investors

• Investors should weigh the company's impressive Q2 2025 earnings beat and strong balance sheet against the persistent headwind of price compression in its core market, which explains the stock's negative reaction and the 'Neutral' analyst rating.
• Given the multi-year development horizon for the promising spatial technology market, the stock may be better suited for long-term investors who can tolerate near-term volatility rather than those seeking immediate gains.
• Monitor upcoming quarterly reports for commentary on margin trends and revenue guidance to assess if the company is successfully navigating the price compression in the single-cell market.
• With the stock at $12.59, below the new $15 price target, the current valuation could be considered a holding pattern, as significant upside appears contingent on the spatial market's maturation, which is still several years away.